28 June 2021
The University of Oxford in partnership with AstraZeneca have begun vaccinations today for a new phase in human trials to test a COVID-19 vaccine ‘AZD2816’ in volunteers against the B.1.351 variant of concern – commonly known as the Beta variant.
The Phase II/III trial, sponsored and led by AstraZeneca will recruit approximately 2,250 participants across UK, South Africa, Brazil and Poland.
AZD2816 will be administered to individuals who have previously been fully vaccinated with two doses of the original Oxford-AstraZeneca vaccine or an mRNA vaccine, at least three months after their last injection. In non-vaccinated individuals, AZD2816 will be given as two doses, four or twelve weeks apart, or given as a second dose following a first dose of original Oxford-AstraZeneca vaccine four weeks apart.
For the UK booster study launch participants must have received two doses of an approved COVID-19 vaccine three to 12 weeks apart more than three months prior to the study.
The new vaccine, known as AZD2816 has been designed using the same adenoviral vector platform developed by researchers at the University of Oxford using the ChAdOx platform technology, with minor genetic alterations to the spike protein based on the Beta (B.1.351, South African) variant.
Professor Sir Andrew J Pollard, chief investigator and director of the Oxford Vaccine Group at the University of Oxford, said: ‘Testing booster doses of existing vaccines and new variant vaccines is important to ensure we are best prepared to stay ahead of the pandemic coronavirus, should their use be needed.’
Dr Maheshi Ramasamy, Principal Investigator at the Oxford Vaccine Group, said: ‘The UK vaccine roll out programme has been incredibly successful at preventing hospitalisations and deaths, but we don’t know how long protection lasts. This study will provide vital evidence on whether further doses including “tweaks” against new virus variants may be needed in the future.’
Sir Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, said: ‘It is important we continue to stay ahead of genetically distinct variants of the coronavirus. AZD2816 should help broaden individuals immune response against emerging variants of concern. Initiating the Phase II/III trial for AZD2816 means we can be prepared should a variant vaccine be required in the future.’
The study aims to assess the immune response to the Beta variant of concern with the new vaccine – for use potentially in combination with the current Oxford-AstraZeneca vaccine – as well as to better understand the disease and associated health problems.
Initial data from the trial is expected later this year and, once available, will be submitted to regulators for assessment as a next-generation booster vaccine and through an expedited regulatory pathway.
Notes to editors:
To arrange an interview, please contact the University of Oxford press office at email@example.com or on +44 (0)1865 280528
For more about the Oxford vaccine project and team: www.ox.ac.uk/covid-vaccine
Images: Credit: University of Oxford, John Cairns https://www.dropbox.com/sh/5jkrr3ynm6pt12y/AAAoMZl57RDIK6guiypQoVQWa?dl=0
D7220C00001 is a Phase II/III partially double-blinded, randomised, multinational, active-controlled trial in both previously vaccinated and unvaccinated adults to determine the safety and immunogenicity of AZD2816, a vaccine for the prevention of COVID-19 caused by variant strains of the SARS-CoV-2 virus.
Trial participants aged 18 years or over who are SARS-CoV-2 nucleocapsid seronegative will be randomised to minimise group differences in terms of age, gender and the presence of comorbidities. Participants will receive intramuscular administration of either Vaxzevria (5 ×1010 viral particles) or AZD2816 (5 ×1010 viral particles). In addition, seropositive participants will be enrolled, with a cap of 10% of the seronegative population, to support exploratory analysis.
AZD2816 has been built using the same adenoviral vector platform as with Vaxzevria, with minor genetic alterations to the spike protein based on the Beta (B.1.351, South African) variant. The Beta variant vaccine contains ten changes across the spike protein, many of which are also seen in other variants of concern, and which lead to effects such as, reduced ability of antibodies induced against the original virus to block cell entry (K417N, E484K, N501Y); increased infectivity compared to the original virus (D614G); reduced sensitivity of neutralising antibodies to the original virus (L452R). These modifications are only minor and in all other ways the two vaccines are the same.
Vaxzevria , formerly COVID-19 Vaccine AstraZeneca and AZD1222
Vaxzevria was co-invented by the University of Oxford and its spin-out company, Vaccitech. It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.
The vaccine has been granted a conditional marketing authorisation or emergency use in more than 80 countries across six continents. More than 600 million doses of COVID-19 Vaccine AstraZeneca have been supplied to 170 countries worldwide, including more than 100 countries through the COVAX Facility.
About the University of Oxford
Oxford University has been placed number 1 in the Times Higher Education World University Rankings for the fifth year running, and at the heart of this success is our ground-breaking research and innovation.
Oxford is world-famous for research excellence and home to some of the most talented people from across the globe. Our work helps the lives of millions, solving real-world problems through a huge network of partnerships and collaborations. The breadth and interdisciplinary nature of our research sparks imaginative and inventive insights and solutions.
Through its research commercialisation arm, Oxford University Innovation, Oxford is the highest university patent filer in the UK and is ranked first in the UK for university spinouts, having created more than 200 new companies since 1988. Over a third of these companies have been created in the past three years.